Once-weekly dual GLP-1 / GIP agonist with biased GLP-1 signaling profile.
Reference facts
- Also known as
- Carmot CT-388
- Category
- GLP-1 & Metabolic
- Mechanism of action
- Once-weekly dual GLP-1 / GIP agonist with biased GLP-1 signaling profile.
- Targets
- GLP-1R, GIPR
- Indications under research or approved
- Obesity, Type 2 Diabetes
- Regulatory status (reference entry)
- Investigational (Phase 2)
- Half-life
- ~7 days
- Sequence notes
- Dual GLP-1 / GIP receptor agonist with proprietary lipid-stalk modification; Roche acquired Carmot 2023.
- Originator / sponsor
- Roche (Carmot Therapeutics)
- First reported
- 2023
Primary References
Explore research articles about CT-388
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.